Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study
1. 当前求助状态已完结, 请及时下载应助文件
2. 系统将在 2025-12-03 15:00:13 删除文件
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/s0140-6736(25)02114-2
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0140673625021142
其他信息:
出版社: Elsevier BV
作者: Mazen Noureddin; Stephen A Harrison; Rohit Loomba; Naim Alkhouri; Naga Chalasani; Muhammad Y Sheikh; Shaheen Tomah; Julio A Gutierrez; Silvia Urbina; John J Suschak; Randy Brown; Ozioma Odili; Jay Yang; Stephine Keeton; Guy Neff; Edward Mena; M Scot Roberts; Sarah K Browne; M Scott Harris
